Understanding the Economic Value of Molecular Diagnostic Tests: Case Studies and Lessons Learned
Ten years after completion of the Human Genome Project, progress towards making “personalized medicine” a reality has been slower than expected. The reason is twofold. Firstly, the science is more difficult than expected. Secondly, limited progress has been made in aligning economic incentives to in...
Main Authors: | Adrian Towse, Diego Ossa, David Veenstra, Josh Carlson, Louis Garrison |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2013-10-01
|
Series: | Journal of Personalized Medicine |
Subjects: | |
Online Access: | http://www.mdpi.com/2075-4426/3/4/288 |
Similar Items
-
Personalized medicine: biomarkers and companion diagnostics
by: Renato Bernardini, et al.
Published: (2018-03-01) -
Companion Diagnostics for Targeted Cancer Drugs - Clinical and Regulatory Aspects
by: Dana eOlsen, et al.
Published: (2014-05-01) -
Recent advances in diagnostic technologies in lung cancer
by: Hye Jung Park, et al.
Published: (2020-03-01) -
Drug-Diagnostics Co-Development in Oncology
by: Jan Trøst eJørgensen
Published: (2014-08-01) -
Cytogenetic and Biochemical Genetic Techniques for Personalized Drug Therapy in Europe
by: Tatjana Huebner, et al.
Published: (2021-06-01)